

## DOMENICA STUDY

**Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus\* Dostarlimab in first line advanced/metastatic setting**

**N° EudraCT: 2021-002124-21 / EU-CT: 2023-510097-14-00**

You have been invited by your doctor to take part in the biomedical research entitled “**DOMENICA** » that could improve the strategy management of your disease. This research is driven (promoted) by **ARCAGY-GINECO** (French group) represented by [Group name] located at [to be completed locally].

Before deciding to take part, it is important for you to understand why the research study is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends and relatives if you wish. Ask your doctor if there is anything that is not clear or if you would like more information. You may wish to discuss the study with your general practitioner or others before deciding.

Your participation in the research is voluntary. You are totally free to accept or refuse to participate and you don't have to justify your decision.

If you do not wish to participate and your decision would have no impact on the quality of your medical care. Whatever your decision, you will receive the best standard treatment available.

Your doctor in charge of this research is fully at your disposal to answer to any question you may have. Take the time to think it over for as long as you think is necessary.

If you agree to participate, the signature of this Informed Consent Form (attached at the end of the document) is mandatory. Please date and sign the consent form in duplicate – one for you and one for your doctor. No procedure relating to the study can be performed before obtaining your consent. This signature doesn't discharge your doctor and the *sponsor\** of their responsibilities towards you.

Moreover, even after you have dated and signed this study consent form, you are still free to withdraw from the study at any time and without providing any reasons.

During the study, your doctor will provide you with all new information that may affect your decision.

This document provides you with information about:

|          |                                                                          |           |
|----------|--------------------------------------------------------------------------|-----------|
| <b>1</b> | <b>DESCRIPTION OF THE STUDY .....</b>                                    | <b>2</b>  |
| <b>2</b> | <b>WHAT ARE THE STUDY PROCEDURES? .....</b>                              | <b>4</b>  |
| <b>3</b> | <b>WHAT ARE THE BENEFITS AND POTENTIAL RISKS OF TAKING PART? .....</b>   | <b>10</b> |
| <b>4</b> | <b>WHAT ARE MY RIGHTS AND THE LEGAL PROVISION FOR THIS STUDY ? .....</b> | <b>13</b> |
| <b>5</b> | <b>GLOSSARY .....</b>                                                    | <b>18</b> |

***\*Definition of words marked with an asterisk in the glossary***

## 1 DESCRIPTION OF THE STUDY

### 1.1 Why is this study conducted?

The current standard treatment for advanced/metastatic endometrial cancer is a **chemotherapy\*** by Paclitaxel and Carboplatin. Despite this treatment, the endometrial cancer can progress in some patients. It's the reason why it's important to find other treatments to limit these relapses at maximum.

One of the therapeutic strategy recently developed, is **immunotherapy\***. This therapy doesn't target directly the tumor, but has an impact on the immune system\* of the patient to be able to recognize, to attack and destroy the cancer cells.

A new drug, named a dostarlimab, and used as **immunotherapy\*** has already been shown to be effective in patients with endometrial cancer and in progression after **chemotherapy\***.

Dostarlimab is a **monoclonal antibody\***. When the **immune system\*** detects a foreign body (virus, bacteria, ...), it produces **antibodies\***. The **antibodies\*** are **proteins\*** which combat the infections. The monoclonal antibodies\* are a kind of specific antibodies produced in laboratory. They can attach to other molecules or cells of your body, and work by helping your **immune system\*** to fight your cancer.

Some cancer cells "hide" from the immune system\* by taking control of "PD-1 way", that the healthy cells use to "tell" to the immune system not to attack them. Dostarlimab attaches to the PD-1 **protein\*** and blocks this way (inhibitors of PD-1), allowing the **immune system\*** to recognize and to attack the cancer cells.

This treatment, which has an important activity, could be proposed earlier in the care of patients with advanced or metastatic endometrial cancer, especially as an alternative to the platinum-based **chemotherapy\***, which is today the standard treatment.

You have an advanced or metastatic endometrial cancer, and the analysis of your tumor detected an abnormality of the **DNA\*** repair system, named **MMR deficient\*** (or **MSI-high\***): it's the reason why we propose you this biomedical research, to evaluate the efficacy of dostarlimab in monotherapy compared to the standard **chemotherapy\***.

The main objective of this research is to see if dostarlimab could help to prevent relapse of your disease.

To be prescribed by a doctor outside clinical research, a drug requires an authorization from regulatory authorities, named « Marketing Authorization » (MA).

The aim of this study is to show that dostarlimab as a single therapy is more efficient than **chemotherapy\***, and reduces significantly the relapses of advanced or metastatic endometrial cancer. We would like that these results could be used to expand the indication of dostarlimab for advanced or metastatic endometrial cancer, to obtain a MA, and to allow earlier access of the drug as part of standard practice.

In this way, it could be prescribed for the care of patients with an advanced or metastatic endometrial cancer at diagnosis, before **chemotherapy\***.

### 1.2 What is the aim of the study?

The DOMENICA study in which **your investigator** doctor invites you to participate, aims to evaluate the efficacy of dostarlimab, as new treatment for your disease.

The study has also other objectives:

**\*Definition of words marked with an asterisk in the glossary**

- To monitor on regular basis the side effects which could occur in participants,
- To analyse your quality of life via self-reported questionnaires to complete throughout the study
- To research, in your tumor or blood samples, some **biomarkers\*** which could explain or predict the efficacy of treatment.

### 1.3 How does this clinical trial work?

This research study will be carried out among 260 patients with an advanced or metastatic endometrial cancer, in more than 80 healthcare facilities in 12 countries (France, Spain, Italy, Canada, United Kingdom, Korea, Singapore, Australia, Turkey, Romania and Poland), during 8 years. Around 130 patients should participate in France (in around 40 sites).

The study is divided in 5 periods:

- the collect of a tumor sample,
- the determination of criteria needed for your participation,
- the allocation of treatment,
- the treatment period
- the follow up period.

After analysis of your tumor sample by the laboratory of your hospital, which showed an abnormality of the **DNA\*** repair system (named MMR deficient or **MSI High\***), another tumor sample will be sent to a central platform where your sample will be analysed to confirm the result.

After this analysis, if the abnormality is not confirmed, you could not participate in the DOMENICA study, and you will receive the **standard treatment\***.

The duration of participation in this research study for each patient is around 5 years. Your doctor will explain when, for how long and how to take the **study treatments\***. Data concerning your health status and any subsequent treatments will be collected.

In order to evaluate the efficacy of dostarlimab, it is necessary to compare this treatment (group 1) to the standard treatment (group 2) which would be proposed to you by your oncologist outside of this study as part of standard care/practice:

- Group 1 (**study treatment\***): dostarlimab during 2 years at maximum or until progression of your disease
- Group 2 (standard treatment): **chemotherapy\*** by carboplatin and paclitaxel during around 5 months at maximum

In order to be able to make comparisons, it is necessary that the distribution between the 2 groups is randomly selected by a computer: this is called **randomization\***. Neither you nor your doctor can choose a group or know, in advance, which group you will belong to. Your doctor will inform you of your group allocation, after a medical examination.

There will be the same number of patients in each treatment group. So you have 1 possibility out of 2 to receive dostarlimab.

To optimise your chance of treatment, your doctor, at the progression of your disease will evaluate if you can change treatment group, this is called a **cross-over\***.

#### **TABLE N°1: DOMENICA STUDY DESIGN**

**Patients with advanced/metastatic  
endometrial cancer, MMR deficient\***

**\*Definition of words marked with a**  
DOMENICA Study (GINECO-EN105b/ENG

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

Publication date : 01/FEB/2022

Page 3 of 21

**Signature of consent form and**

## 2 WHAT ARE THE STUDY PROCEDURES?

### 2.1 Collect of tumor sample

By signing the consent form, you will accept to give a tumor sample, already collected during a previous surgery or biopsy\*

Indeed, before to allocate you a treatment, it's necessary to confirm the result of MMR test realized by the laboratory of your hospital (from a tumor sample): for this, a tumor sample will be sent to central platform for analysis.


You could be randomized in the study, only if this platform confirms that your tumor has some mutations, known as « MSI-high » or « mutations dMMR\* ».

### 2.2 Your treatment

If you agree to take part in the study, and if your tumor has some mutations, known as « MSI-high » or « mutations dMMR\* », your treatment will be randomized, and you will receive:

- Either the experimental treatment intravenously through an infusion (group 1): dostarlimab at a dose 500mg every 3 weeks during around 3 months (a total of 4 doses), then at dose 1000mg every 6 weeks during 2 years maximum (according to your status).
- Or the standard treatment intravenously through an infusion (group 2): a chemotherapy-based carboplatin and paclitaxel at dose 175mg/m<sup>2</sup>, every 3 weeks during around 5 months (a total of 6 doses). If your disease progresses.

**TABLE N°2: TREATMENT DESIGN**



If your doctor thinks that you may benefit from the second treatment in the study, you could receive it after sponsor approval.

If your disease progresses, if side effects become severe or if new information indicates that this treatment is no longer suitable for you (whether it is the study treatment\* or the standard treatment), you will be informed by your doctor who will offer you other medical care options.

***\*Definition of words marked with an asterisk in the glossary***

### **Prohibited treatments during study**

If you agree to take part in the study, and if your tumor has some mutations, known as « MSI-high » or « mutations dMMR\* », there are certain groups of medications that you will not be allowed to take while you are in this research because of the way they interact with study treatments\*. These medications include other approved or investigational anticancer treatment, investigational drug, live vaccines, immunosuppressive agents and systemic corticosteroids.

You should inform your doctor of any medications that you are taking, and if necessary, he will try and find an alternative for you. If there is no alternative you may not be able to take part in this research. You will not be asked to stop any medications that you need.

Some herbal and dietary supplements and some vaccinations may interact with study treatments\*, so need to be discussed with your doctor before they are taken.

If you were to take any of these treatments, or if you are in doubt, contact your doctor.

### **2.3 Exams and visits schedule**

If you agree to participate in this research, in addition of the visits and exams realized in the standard care, you will have additional blood samples taken and scans will be performed regularly and according to the schedule below (chapter 2.3.5) to assess your state of health.

You will also be asked to fill regularly, the Quality-of-Life questionnaires and questionnaires on potential undesirable effects that could occur after the 1st dose of treatment:

- Four questionnaires to assess your quality of life (QLQ-C30, EORTC QLQ-CIP20, EORTC QLQ-EN24 and EUROQOL EQ-5D): about 80 questions in total;
- Approximately 60 questions to collect potential side effects.

These questionnaires completion will take about 35 minutes.

Moreover, if you are over 70 years old, you will be asked to complete three additional questionnaires before the start of treatment (ADL, IADL and HADS): about 30 questions in total, requiring 10 minutes for completion.

#### **2.3.1 Prior to treatment**

Once you have given your consent to participate in this study (by signing two copies of the consent form), you will have a visit with your doctor during which he will ask you about the history of your disease, your possible past or current diseases, the treatments you have already received as well as those you are currently taking.

During this visit an extensive medical examination will be carried out including:

- a complete physical examination,
- a biological testing\* (a blood sample of about 20 ml / 4 tubes),
- an evaluation of your thyroid through blood sample,
- an urine analysis, an electrocardiogram (**ECG**)\*,
- a pregnancy test ((if you are of childbearing age)
- an imaging (CT scan or **MRI**\*).

In case some of these evaluations have already been done very recently, they will not need to be repeated.

Once the exams realized and the results received, your investigator doctor\* will decide if you can participate to this study. If it's the case, your investigator doctor\* will give you a tablet computer to complete at home and during the visits the different questionnaires on your quality of life and the potential undesirable effects, during all the study. You will keep this tablet during your participation in the study and after the end of the study.

***\*Definition of words marked with an asterisk in the glossary***

DOMENICA Study (GINECO-EN105b/ENGOT-en13) – Informed Consent Form - Version 4.0 – 06/05/2024 – From FORM 109-08 – Application date : 01/FEB/2022

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

If you sign the consent form, you will agree also:

- to give an additional blood sample for future exploratory researches on the factors which could affect the treatment response. This blood sample (around 30mL) will be collected at the same time that the blood sample for biological testing\*
- to give a tumor sample collected during a previous surgery. This tumor sample will be sent to a central laboratory for biomarkers\* analysis.
- to give additional blood sample, if you are in group 1, for optional biological research to better understand treatment activity and the effect of antibodies on its presence in blood.

Your participation to this study will depend on the results of exams. If they are conform to the inclusion criteria, you could be randomized in one of the 2 treatment arms (groups) and the treatment will start within 7 days. Your investigator doctor\* will inform you of your treatment group as soon as he will have knowledge.

### **2.3.2 During the treatment phase**

If the assessments of selection period have confirmed that you can participate to the study, you will have a visit with your investigator doctor\*, during which your possibility to start the treatment will be confirmed. Then, some visits will be realized in order to monitor your health status and the effect of your treatment according to the following schedule:

- If you are in the group 1 (dostarlimab) : you will have a visit with your investigator doctor\* every 3 weeks (i.e . 4 visits), then, every 6 weeks until the end of treatment (i.e. for 2 years at maximum)
- If you are in the group 2 (chemotherapy\* per carboplatin and paclitaxel), you will have a visit with your investigator doctor\* every 3 weeks (i.e . 6 visits)

If you change treatment group at progression of your disease (cross-over\*), the frequencies stated above will remain unchanged and all assessments detailed below will be performed.

During each visit, some exams will be realized, especially:

- a complete physical examination,
- a **biological testing\*** (blood sample of about 20mL (i.e. 4 tubes),
- an urine testing,
- an evaluation of your thyroid through a blood sample,
- some questions on your health status since your last visit, and a collection of the treatments that you have taking and/or are currently taking.

An evaluation of your tumor by imaging will be realized every 6 weeks the first 6 months, then every 9 weeks for the remaining of the 1st year, then, every 12 weeks.

Some additional exams could be requested by your investigator doctor\*:

- A coagulation test
- A CA-125 dosage (marker of your disease). If there is an anomaly of this dosage, a radiologic evaluation by scan or MRI\* could be requested by your investigator doctor\*
- An electrocardiogram (ECG) \*

You should also complete (through a tablet computer) a questionnaire on your potential undesirable effects that you can have (every 3 weeks until the 6<sup>th</sup> treatment dose, i.e. until week 18, then 6 weeks), and some different questionnaires on your quality of life (every 12 weeks).

3 weeks after the 1st dose of treatment and during your visit at 5th cycle (before the administration of your treatment), a blood sample around 30mL (i.e. 3 tubes) will be realized to be store for Translational Research\*. If you agree and are in group 1, blood samples for optional biological research will be taken before and after 1st dose of study treatment, then at 2nd, 4th, 5th, and 9th cycle (before the administration of study treatment).

---

***\*Definition of words marked with an asterisk in the glossary***

### 2.3.3 At the end of the treatment phase

Regardless of your treatment group, you will have a consultation with your doctor within 30 days of treatment discontinuation and prior to switch treatment group (cross-over\*) if your disease progresses and sponsor\* provided approval.

Usual medical examinations necessary for the monitoring of your health status will be carried out: a complete physical examination, an evaluation of possible adverse effects, a **biological testing\*** (blood sample of about 20 mL, i.e. 4 tubes), some questions on your health status since your last visit and a collection of the treatments you have taken and/or are currently taking.

You should also complete (through a tablet computer) a questionnaire on your potential undesirable effects that you can have.

Some additional exams could be requested by your investigator doctor\* :

- A coagulation test
- A CA-125 dosage (marker of your disease). If there is an anomaly of this dosage, a radiologic evaluation by scan or MRI\* could be requested by your investigator doctor\*
- An electrocardiogram (ECG) \*

If you are in Group 1 and agreed to participate in the optional biological research, two additional blood samples will be collected.

### 2.3.4 Follow-up after treatment

Thereafter, if your disease has not progressed and you have stopped your treatment for other reason, your investigator doctor\*, will request you to realize other visits every 6 weeks during the first 6 months then every 9 weeks during the remaining of the 1st year, then every 3 months to monitor your health status, until the progression of your health. A systematic radiologic evaluation will be realized.

During this visit, the following examinations will be carried out: a physical examination, an evaluation of possible adverse/undesirable effects and whether you receive any other subsequent anticancer treatments.

You should also complete (through a tablet computer) some different questionnaires on your quality of life every 12 weeks and a questionnaire on your potential undesirable effects that you can have every 6 weeks.

In case of progression, and if you agree, a blood sample about 30mL (i.e.3 tubes) and a tumor sample will be stored for Translational Research \*.

In case your disease progresses for the time during the follow up phase, your doctor will evaluate if the cross-over\* to the other group of treatment can be possible. If so, all assessments explained in the section 2.3.3 will be performed before starting the new treatment.

In case you are in Group 1 and agreed to participate in the optional biological research, two additional blood samples will be collected 12 weeks after the end of treatment.

***\*Definition of words marked with an asterisk in the glossary***

### 2.3.5 General overview of planned visits during the study

| Procedures                                                                    | Visits                           |                                                                                                        |                                                                                |                                   |
|-------------------------------------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------|
|                                                                               | Maximum 28 days before treatment | Phase of treatment                                                                                     | End of treatment (within 30 days after last dispensation or before cross-over) | Follow-up after treatment         |
| Informed Consent Signature                                                    | X                                |                                                                                                        |                                                                                |                                   |
| MMR/MSI Status, local and central testing                                     | X                                |                                                                                                        |                                                                                |                                   |
| Medical History                                                               | X                                |                                                                                                        |                                                                                |                                   |
| Physical examination                                                          | X                                | Before each dispensation of treatment                                                                  | X                                                                              | X                                 |
| Tumor assessments by Imaging                                                  | X                                | Every 6 weeks during 6 months, then every 9 weeks until the 1st year of treatment, then every 12 weeks |                                                                                |                                   |
| Electrocardiogram (ECG) *                                                     | X                                | <i>At investigator's discretion</i>                                                                    |                                                                                |                                   |
| Biological testing*<br>+ urine test<br>+ CA-125 test                          | X                                | Group 1 :<br>Every 3 weeks until week 9; then every 6 weeks<br>Group 2<br>every 3 weeks                | X                                                                              |                                   |
| Pregnancy test (if applicable)                                                | X                                | Before each dispensation of treatment                                                                  |                                                                                |                                   |
| Questionnaires on Quality of Life to be completed through a medical device    |                                  | Every 12 weeks                                                                                         |                                                                                |                                   |
| Questionnaire on undesirable effects to be completed through a medical device |                                  | Every 3 weeks until the 6 <sup>th</sup> treatment dose, i.e. until, i.e; week 18, then 6 weeks         |                                                                                |                                   |
| Blood sample for <i>biomarkers</i> analysis <sup>(1)</sup> (mandatory)        | X                                | Before the 2 <sup>nd</sup> e and 5 <sup>th</sup> et 5 <sup>ème</sup> dispensations of treatment        |                                                                                |                                   |
| Tumor sample for <i>biomarkers</i> analysis <sup>(1)</sup> (mandatory)        | X                                |                                                                                                        |                                                                                |                                   |
| PK and IG * when treated by dostarlimab (group 1)                             |                                  | Before treatment at cycles 1, 2, 4, 5, 9 (PK and IG) and PK only after the treatment at Cycle 1        | End of treatment visit only                                                    | 12 weeks after end of dostarlimab |
| Dispensation of dostarlimab (group 1)                                         |                                  | Every 3 weeks during 3 months, then every 6 weeks for a maximum of 2 years                             |                                                                                |                                   |
| Dispensation of chemotherapy per Paclitaxel and carboplatin (group 2)         |                                  | Every 3 weeks during 4 months                                                                          |                                                                                |                                   |

(1) In case of progression, and you agree, a blood sample about 30mL (i.e.3 tubes) and a tumor sample will be stored for Translational Research\*

***\*Definition of words marked with an asterisk in the glossary***

DOMENICA Study (GINECO-EN105b/ENGOT-en13) – Informed Consent Form - Version 4.0 – 06/05/2024 – From FORM 109-08 – Application date : 01/FEB/2022

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

Page 8 of 21

## 2.4 Biological Research

The DOMENICA study consists of main research and biological research called **translational research\***. The purpose of this **translational research\*** is to determine why different people may react differently to medicines.

**Biomarkers\*** are molecules (for example, **proteins\***, lipids or genes) found in our blood or biological tissues. Different **biomarkers\*** may affect how a disease progresses or not, as well as how a body reacts to drugs like those provided in this study. The **sponsor\*** of this study, ARCAGY-GINECO, would like to determine if there is a link between the presence of **biomarkers\*** in the tumor cells and the efficacy/side effects of the **study treatments\***. The goal of this research is to determine if some individual **biomarkers\*** or tumor-based characteristics would allow, in the future, to identify the patients who benefit most from this new treatment.

If you decide to participate in the main study, then you will also participate in the **translational research\*** requiring:

- a blood sample about 30mL (i.e.3 tubes) before the study treatment\*, during a blood assessment realized for your care,
- a blood sample about 30mL (i.e.3 tubes), during your visit for the second cycle of your treatment
- a blood sample about 30mL (i.e.3 tubes), during your visit for the fifth cycle of your treatment

In case of progression, and if you agree, a blood sample about 30mL (i.e.3 tubes) and a tumor sample will be stored for Translational Research\*.

2 optional samples of your tumor, which have been taken during a previous surgery before your inclusion in the study, in addition to the tumor sample needed for the confirmation of MMR status.

By agreeing to participate to this research you will allow the collection of important data on your disease which will improve the scientific knowledge about it and improve the ways to treat it. The results of this research will not be added to your medical file and will of course remain anonymous.

The genetic characteristics of your tumor will be analyzed. It will be necessary to compare these characteristics to those of your **constitutional DNA\*** (your genetic characteristics located in all the cells of your body). The blood sample taken before treatment will be used as comparator.

These analyses will not be carried out in order to study your own genetic characteristics, nor to identify you, but in order to better understand the mechanisms of your disease and its treatment.

## 2.5 Optional secondary biological research

To this main study we added a secondary optional research including **pharmacokinetic\*** study to define through the treatment phase the dostarlimab rate in your blood (PK\*) and specific antibodies\* that bind to dostarlimab (IG\*). The purpose of this secondary optional research is to better understand the study treatment activity and the effect of the antibodies on its rate. If you agree to participate in this secondary optional study, you will have to in the group 1, i.e. being treated with dostarlimab. Extra blood samples will be collected at different time:

- Blood sample of 2mL and 4 mL will be drawn before administration of study treatment at Cycles 1, 2, 4, 5, 9; and then at end of treatment visit and then 12 weeks after
- Blood sample of 2mL after administration of study treatment at Cycle 1

**\*Definition of words marked with an asterisk in the glossary**

DOMENICA Study (GINECO-EN105b/ENGOT-en13) – Informed Consent Form - Version 4.0 – 06/05/2024 – From FORM 109-08 – Application date : 01/FEB/2022

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

## 3 WHAT ARE THE BENEFITS AND POTENTIAL RISKS OF TAKING PART?

### 3.1 What are the benefits of taking part?

We hope that dostarlimab is more efficient than chemotherapy\*, and reduces significantly the relapses of advanced or metastatic endometrial cancer.

It could have access sooner to the therapeutic innovation, especially immunotherapy\*.

However, you may not benefit from participating in this study. Your condition may remain the same, improve or worsen. Your participation will not limit the access to the standard treatments, in case of benefit or progression after the treatments dispensed in this study.

By participating in this research, you will be helping scientists and clinicians better understand the disease and improve future treatment options. The information from this study will also hopefully help future endometrial cancer patients.

### 3.2 What are the potential risks and disadvantages of taking part?

**Study treatments\*** may be responsible for side effects. All of them are not identified, even though drugs proposed in this study have all been marketed in many countries worldwide for several years. Most of them are variable from one patient to another. They can be mild, moderate or sometimes severe. Some may go away as soon as you stop taking the **study treatment(s)\***. In some cases, they can be serious, long-lasting or may never resolve (irreversible). If you experience any side effect, your doctor will give you medicines to help attenuate them.

In addition, by combining several drugs, side effects may be more frequent and/or more intense than when taking only one of these drugs.

It is important that you inform your investigating physician of any medication, dietary supplement, **phytotherapy\***, that you are taking or intend to take during the study as interactions may exist between the drugs.

**Tolerance\*** of **study treatments\*** will be assessed at each visit by your doctor. Additional treatments may be prescribed to control side effects. If they are significant, your doctor may change the treatment doses or stop **study treatment(s)\*** for a given time or permanently. Likewise, it is important that, apart from these regular visits, you contact quickly your doctor in the event of uncomfortable **toxicity\***.

The following side effects may occur based on the experience from other patients who have been treated with dostarlimab. They are listed according to their frequency regardless of their severity. **If you experience any of the side effects listed below, please contact your doctor immediately.**

#### 3.2.1 Dostarlimab side effects

##### Very common (> 10 %)

- **Anaemia:** decreased number of red blood cells (which can lead to fatigue or breathing difficulties and require a blood transfusion)
- **Increase of transaminases** (AST, ALT which are produced by the liver)
- **Gastro-intestinal disorders:** nausea, diarrhoea, vomiting
- **Cutaneous reactions:** skin rash\*, prurit (itching)

*\*Definition of words marked with an asterisk in the glossary*

**- Fever**

- **Hypothyroidism:** insufficient secretion of hormones by thyroid, which could cause especially fatigue, hypothermia and weight gain

**Common (1-10 %)**

- **Adrenal insufficiency:** insufficiency of secretion of steroid hormones by adrenal, which could lead to important fatigue, a decrease of blood pressure and a loss of weight

- **Hyperthyroidism:** important secretion of hormones by thyroid, which could cause especially weight loss, diarrhea, nausea, heart palpitations, and insomnia

**- Pneumonia**

- **Pancreatitis:** pain in the upper abdomen. This could become severe and cause nausea and vomiting, fever, and rapid heart rate

- **Gastro-intestinal disorders:** colitis

- **Flu like syndrome** with fever, myalgia (muscular pains), chills

- **Nephritis :** inflammation of kidneys, which could cause some disorders of substances by the kidney

**Uncommon (0,1-1%)**

- **Auto immune haemolytic anaemia:** dysfunction of immune system\* which produces auto antibodies\* which attack the blood cells as they were substances totally foreign to the human body, which could cause fatigue and shortness of breath

- **Inflammation of thyroid gland** (thyroiditis), which can result in a malfunction of the thyroid gland (resulting in hypo or hyperthyroidism)

- **Inflammation of pituitary gland,** located in the brain (Hypophysitis) and which could cause pallor, hair loss and slow speech

- **Diabetic ketoacidosis:** increase of blood acidity, related to the accumulation of toxic substances for the organism and caused by the lack of insulin

- **Type 1 diabetes:** excess of blood sugar that can lead to abnormal thirst, and fatigue

- **Immune-mediated arthritis:** inflammatory articular disease characterised by articular pains

- **Muscular rheumatism** (Polymyalgia rheumatica)

- **Uveitis :** Inflammation of eye

- **Myasthenia :** disease which can lead fatigue and muscle weakness

- **Infection in the brain** (encephalitis)

- **Inflammation of the heart muscle** (myocarditis)

- **Inflammation of the liver** (hepatitis)

- **Inflammation of the lining of the stomach** (Gastritis)

- **Inflammation of the food pipe** (Esophagitis)

- **Inflammation of the small intestine** (Enteritis)

- **Inflammation of blood vessels in the gastrointestinal tract** (Vasculitis gastrointestinal)

***\*Definition of words marked with an asterisk in the glossary***

- **Inflammation of the muscle** which can cause weakness, swelling and pain (Myositis)
- **Inflammation throughout the whole body** leading to high or low temperatures, low blood pressure, increased heart rate, increased rate of breathing and low or high white blood cell count (Systemic Inflammatory Response Syndrome)
- **Infusion-related reactions** which can occur within 24 hours after receiving an intravenous infusion, or which can be delayed for up to about 2 weeks. Infusion-related reactions may include dizziness or fainting, flushing, rash, fever, chills, shortness of breath, increased or decreased blood pressure, increased heart rate, swelling of the lips, tongue or face, feeling sick to your stomach, back pain or pain at the site of infusion. Although infusion-related reactions are usually reversible, they can be severe or life threatening. (Infusion related reactions)

There are rare but serious immune-related adverse events which have been seen when dostarlimab was used alone or in combination with other medicines:

- Overactive immune-system cells which damage body tissues and organs leading to signs of uncontrolled fever, enlarged spleen, low blood count and liver test abnormalities.
- A neurological disorder where the immune system\* attacks part of the peripheral nervous system that can cause tingling in the feet and hands, pain, muscle weakness, and problems with coordination (Guillain-Barre syndrome).
- Muscle weakness, twitching, cramping or inability to move (peripheral motor neuropathy)
- Muscle pain and weakness, swollen, red or thickened skin (eosinophilic fasciitis)

There may be other risks called class effects that have been seen in patients receiving other drugs that work like dostarlimab. These effects could also occur with dostarlimab. They are potential risks but not known as side effects for dostarlimab so far. The most significant class related side effects are “immune-related”, meaning side effects caused by increased activity of the immune system\*, which can affect multiple organs of the body including bowels, hormone glands, heart, lungs, liver, skin, muscles and joints and nerves.

The side effects listed below require immediate medical attention or advice. **Call the study doctor right away if you have any of these side effects.**

- Respiratory: shortness of breath, rapid breathing, new or worse cough
- Gastrointestinal: diarrhoea, stools that are black or bloody, stomach area pain, nausea or vomiting
- Kidneys: dark or bloody urine, urinating more often than usual
- Musculoskeletal: chest pain, muscle pain or weakness
- Cardiac: fast or unusual heartbeat
- Skin: rash, itching, blisters, pale or yellow skin
- Eyes: yellowing of the whites of your eyes, blurry vision
- Brain: abnormal thinking, confusion, personality changes, headache and neck stiffness
- General: bleeding or bruising more easily than normal, feeling cold, hair loss, dizziness or fainting, feeling tired or weak, fever or chills.

### **3.2.2 Chemotherapy side effects**

Chemotherapy\* treatments (carboplatin or paclitaxel) can cause specific side effects. Your doctor will explain these side effects.

***\*Definition of words marked with an asterisk in the glossary***

DOMENICA Study (GINECO-EN105b/ENGOT-en13) – Informed Consent Form - Version 4.0 – 06/05/2024 – From FORM 109-08 – Application date : 01/FEB/2022

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

### 3.2.3 Risks linked to study procedures

CT scans and **MRIs\*** may involve injection of a **contrast agent\***. As with any product, there is a risk of an allergic reaction to that product.

Needle pricking during injection of the **contrast agent\***, during treatment administration or blood sampling can cause pain, swelling, bruise, irritation or redness.

During the **electrocardiogram\***, you may experience itching or bruising on the skin where the patches were placed.

#### 3.2.3.1 Pregnancy and breastfeeding

As the sponsor\* of this research does not know the effects of the study products on an unborn child or newborn, you are not allowed to participate in this research if you are pregnant or if you planned to become pregnant during the study period.

Women of childbearing potential can only participate in this research if they use effective contraceptive methods. You will be required to use one highly effective form of contraception with your partner starting with the Screening Visit through 180 days after the last dose of study therapy.

You will need to perform a pregnancy test before starting the study and regularly during the study if your doctor deems it necessary. The pregnancy can be reliably detected through the pregnancy test just a few days after the conception.

Breastfeeding women cannot participate in this research because the treatment may pass into the child's body during breastfeeding and the problems it may cause the child is not known. Therefore, breast-feeding is not allowed during treatment and for up to 180 days after the last dose of the study treatment\*. During the study and up to 6 months after the last dose of study treatment\*, please inform immediately your doctor if pregnancy occurs or is suspected. Your study treatments\* will be stopped immediately. If you and your partner agree, the sponsor\* will ask you for information on the outcome of your pregnancy (such as your health, the date of conception, the progress of your pregnancy, the treatments that you could receive and at the birth of the child, information about his health).

## 4 WHAT ARE MY RIGHTS AND THE LEGAL PROVISION FOR THIS STUDY ?

Medical research is strictly regulated by law. The legal provisions guarantee a number of rights.

**Please read this section carefully.**

### 4.1 Conditions for participation

Your participation in the study is free and voluntary. If you agree to take part to this research, you will need to sign a consent form to participate.

You cannot have participated in any other interventional study in the 3 months preceding the start of your participation to DOMENICA study, and you will not be allowed to participate in any other study simultaneously to your participation in the DOMENICA study.

### 4.2 Commitment from your side

During your involvement in the study, your duty is to properly follow the instructions given by your doctor on the study protocol. It is important to come to the study site for every planned visit to receive treatment,

***\*Definition of words marked with an asterisk in the glossary***

DOMENICA Study (GINECO-EN105b/ENGOT-en13) – Informed Consent Form - Version 4.0 – 06/05/2024 – From FORM 109-08 – Application date : 01/FEB/2022

Document to be collected in two original copies, one to be given to the patient and the other to be kept by the investigator.

perform the examinations, including imaging, and be assessed by your doctor. It is important that you inform your doctor of any change in your state of health, even if it is not related to the *study treatments\** and/or any change in medication intake.

#### **4.3 Right to withdrawal**

You are still free to withdraw your consent at any time without giving any reason and stop taking part to the study. Your decision will not affect your medical care now or in the future. To ensure and preserve your safety, we ask you to inform immediately your doctor about your decision. In this case your doctor will offer you, if you like it, the suitable treatment(s).

In the event of withdrawal, your personal data and the blood or tumor samples already collected may be analyzed unless you express your refusal.

#### **4.4 Alternative treatments**

Currently, there is no other treatment available. Your doctor will discuss with you the supportive care options and the risks and benefits associated with all of them.

#### **4.5 Insurance and compensation arrangements**

The sponsor\* has taken out a insurance with the company (local company) (Contract N°.XXXXX) in accordance with local law to cover risks in connection with your participation in this study.

#### **4.6 Compensation**

You will not receive any compensation for taking part in the study. You will not have to spend any money to participate in the study. The *study treatments\** will be given to you free of charge and you will not be charged for study consultations nor exams.

#### **4.7 Approval from Competent Authorities**

This Protocol has been approved by local CA on the xx/ xx /xxxx and got the favorable opinion of the Ethic Committee YYYY on the xx/ xx /xxxx. The latter task is to verify whether the conditions for your protection and your rights have been respected in accordance with the law (local regulation).

#### **4.8 Right to confidentiality**

Your identity will never be revealed. To carry out this research, your doctor will send data from your medical file to ARCAGY-GINECO. Transmission and data communication will be done under the rules of professional secrecy.

Representatives from ARCAGY-GINECO will be able to see your hospital or clinic records. This access can only be carried out under the responsibility of your doctor.

In addition, in case of an inspection mandated by the competent regulatory authorities, the inspectors in charge of this mission of public interest may be required to consult your personal data collected as part of the study and thus have direct access to your medical files.

***\*Definition of words marked with an asterisk in the glossary***

All persons having access to these medical and personal data are required not to disclose or reveal such information. They are subject to the conditions of professional secrecy.

#### **4.9 Rights regarding the treatment of your personal data**

ARCAGY-GINECO, 8 rue Lamennais 75008 Paris, is responsible for the treatment of data. In accordance with the articles 6.1.e and 9.2 of the GDPR, your personal data, including your medical data, are processed for the performance of a task carried out in the public interest and for scientific research purposes. In addition, in accordance with the article 6.1.c, your personal data are processed to meet ARCAGY-GINECO legal obligations.

ARCAGY-GINECO, as data controller, committed to complying with the referent methodology of “Commission Nationale Informatique et Libertés” (CNIL). This methodology gives the conditions under which the treatment must be realized to ensure an integrity and an optimal confidentiality of your data.

All your personal data will be kept during 25 years after the end of study (i.e. after that all the patients have finished their treatment)

If you note that the personal data's treatment by ARCAGY-GINECO is not confirm to the regulation, you can exercise a right of claim to the control authority, the “Commission Nationale de l'Informatique et des Libertés (CNIL), according to the dispositions of law regarding the data processing, data files and liberties” (french law n°78-17 of 6 January, 1978) and to the General data protection regulation (UE) 2016/679, 27<sup>th</sup> of April, 2016.

You could exercise your rights of access, correction or limitation of you personal data by informing your doctor or the Data Protection Officer of ARCAGY-GINECO ([dpo@arcagy.org](mailto:dpo@arcagy.org)).

##### **4.9.1 Type of personal data**

In order to meet the study objectives, ARCAGY-GINECO will collect data relating to your health and to the care you will receive. In addition to these data, genetic information on surgery tumor samples will be collected and analyzed by ARCAGY-GINECO.

##### **4.9.2 Respect of your anonymity**

According to the dispositions of law regarding the data processing, data files and liberties (french law n°78-17 of 6 January, 1978) and to the data protection regulation (UE) 2016/679, a treatment of your personal data will take place to analyse them in view of research's purpose.

If you sign the informed consent form, you are giving the permission to your doctor to use or share your medical data. These data will be forwarded by your doctor to ARCAGY-GINECO. Only the data that we need for the research's objectives will be collected.

An identification number has been allocated to you at the beginning of the study. All the data will be identified by this code and your initials, so that we don't know your identity. No data which identifies you directly (name, first name, address, social security number) will be collected by ARCAGY-GINECO. Only your doctor knows the correspondence between this number and your identity which will never revealed.

##### **4.9.3 Transmission of data**

The DOMENICA study is an international study conducted by ARCAGY-GINECO. In this context, the medical data could also, in conditions that ensure their integrity and confidentiality, be forwarded to French and foreign Health authorities, and their partners.

ARCAGY-GINECO commits to take all the necessary measure to ensure that its partners ensure the same level of data protection, regardless of the country. This is a level of data protection equivalent to that practiced in the European Union. If data have be transmitted to a country where data protection is less rigorous, ARCAGY-GINECO will ensure that your rights are respected by establishing a contract with the partner.

Some medical data could also be forwarded anonymously to the pharmaceutical company which produces dostarlimab. This is only for tolerance/safety purposes and, in accordance with the regulations, it will allow this company to have all information for the monitoring of this medicine/drug.

#### **4.9.4 Reuse of data**

The regulations governing research targeting humans provide that ARCAGY-GINECO may use your data collected as part of this research for others researchs in the future. The objective is to improve the scientific knowledge (biological and medical) in cancer area.

#### **4.9.5 Right of data access**

You have a right of access to your electronic data.

#### **4.9.6 Right to limit, rectify and oppose data**

You may request that all or part of your data be rectified if you find it to be inaccurate or incomplete.

You also have the right to oppose the use of your data. ARCAGY-GINECO will not collect any further data. However, ARCAGY GINECO may not delete your data already collected to meet the legal obligations and protect the scientific integrity of the study.

**Finally, you have the right to limit the use of you data. For example, the treatment of your data may be temporarily frozen in case of a request for rectification or opposition. ARCAGY-GINECO will then retain your data but will not use it for the duration of the analysis and treatment of your request, i.e. the verification and if applicable the correction of your data or their deletion.**

#### **4.9.7 In case of data integrity breach**

The appropriate precautions are taken by ARCAGY-GINECO, to guarantee the integrity and confidentiality of your personal data. However, if ARCAGY-GINECO would detect a dysfunction causing the deterioration, the loss or the diffusion of your personal data, your doctor would be informed very quickly to forward you the information.

### **4.10 Storage and use of biological samples**

Blood and tumor samples collected as part of the DOMENICA study will be stored at the health facility where you are being followed/treated. They will be stored there under appropriate conditions and in accordance with the current regulation until they are transferred at the central laboratory of the Curie Institute -Hôpital Claudius Régaud, 26 rue d'Ulm, 75005 Paris, France for storage. Subsequently, they will be transferred to ARCAGY-GINECO's partner laboratories for analysis. These laboratories may be located inside or outside the European Union.

Your samples will be analyzed during or at the end of the DOMENICA study, therefore several months or years after signing your consent. If any of your blood or tumor samples have not been fully used for the analysis performed at the end of the study, they will be stored, and if you give your written consent at the end of this document, additional scientific research on endometrial cancer may be carried out by ARCAGY-GINECO until all your biological material is fully used.

***\*Definition of words marked with an asterisk in the glossary***

All current and future analyses performed on these samples will be carried out only for research purposes. Your samples will be handled and stored according to the current laws. Your samples will be labelled with a unique number, but without any personal identifiable details such as your name or date of birth. To guarantee the confidentiality of information, data concerning the collection of blood and tumor samples will be kept in a secure database.

Your samples may be stored by ARCAGY-GINECO after the end of the DOMENICA study without time limit and for up to all biological material is fully used.

The results of tests on your biological samples can be compared and combined with those of other studies on the treatment under evaluation. In addition, they can be compared to medical information collected about you during the study, but only if this information can help us to better understand how patients respond to the *study treatments*\*. The results of these tests will have no influence on the medical management of your disease.

At any time, you can withdraw your consent to the future use of your samples by communicating your request to your doctor. He will send it to ARCAGY-GINECO and then make sure that your samples still available are destroyed. Your request will be recorded in your medical file. This will not affect the medical care you will receive or the data already generated with your samples.

Furthermore, if you withdraw your consent to participate in the research, samples already collected may still be used, unless you expressly request that they will be destroyed or if local laws require their destruction. However, any results generated before you stopped participating may be kept by ARCAGY-GINECO.

#### **4.11 Right to information**

If you have any questions about this study, please ask your doctor who will provide you with all the information you would need on the study drug or your participation.

Throughout the course of the study, you will have the right to be informed on this research. Your doctor must also provide you with all new information that may modify your decision.

#### **4.12 Right of access to global results from the research**

Your participation in this study allows improvement in biological and medical knowledge. According to the provision of law n°2002-303 of March 4, 2002 relating to the rights of patient, you are allowed to know the overall results of this study by making a request to your doctor. The design of the protocol and its results will be published and available in at least one public website (<http://www.arcagy.org>).

The study results will be published in a scientific journal. They will also be presented at international scientific conferences. These results will be strictly anonymous; it will be impossible to identify you. It may take a long time for the first results to be presented (between 2 to 7 years after the start of your participation).

***\*Definition of words marked with an asterisk in the glossary***

## 5 GLOSSARY

Definition of words marked with an asterisk in the glossary

|                                |                                                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>DNA</b>                     | Deoxyribonucleic Acid (DNA) is a molecule present in all living cells, which includes all the information necessary for the development and functioning of an organism. This molecule is transmitted during reproduction, in an integral way or not, it is a support of heredity.                                                                               |
| <b>Constitutional DNA</b>      | Unlike tumor DNA that has changed over time, your constitutional DNA represents you. By comparing the genetic characteristics of your tumor cells with those of your constitutional DNA, it is possible to know if the observed differences are specific to your disease, or if they are your own characteristics that are naturally present in all your cells. |
| <b>Antibodies</b>              | Proteins produced by the body's immune system*, which is able to react in the presence of a substance that the body recognizes as foreign.                                                                                                                                                                                                                      |
| <b>Biological testing</b>      | Values of the different medical biology tests carried out on a blood test. This assessment is used by your doctor to complete the medical examination.                                                                                                                                                                                                          |
| <b>Biomarkers</b>              | Substances (e.g. <i>proteins</i> *, lipids, genes, etc.) present in the blood or biological tissues whose measurement or evaluation allows researchers to better understand the effects of a disease or treatment.                                                                                                                                              |
| <b>Biopsy</b>                  | Procedure to take a small sample of a body tissue for an examination                                                                                                                                                                                                                                                                                            |
| <b>Chemotherapy</b>            | Treatment with medicine to treat a cancer                                                                                                                                                                                                                                                                                                                       |
| <b>Electrocardiogram (ECG)</b> | Analysis of cardiac electrical activity. The latter is measured using electrodes placed on the skin and connected to a machine.                                                                                                                                                                                                                                 |
| <b>Enzyme</b>                  | <i>Proteins</i> * which role is to accelerate chemical reactions in the body.                                                                                                                                                                                                                                                                                   |
| <b>Cutaneous/ Skin rash</b>    | Appearance on the skin of pimples, patches or redness.                                                                                                                                                                                                                                                                                                          |
| <b>Immunotherapy</b>           | Treatment that aims to stimulate the body's immune system* against cancer cells                                                                                                                                                                                                                                                                                 |
| <b>MRI</b>                     | Magnetic resonance imaging (MRI) is a medical imaging technique that allows for two- or three-dimensional views of the inside of the body in a non-invasive manner with a relatively high contrast resolution.                                                                                                                                                  |
| <b>Investigator doctor</b>     | Doctor in charge of biomedical research in your hospital                                                                                                                                                                                                                                                                                                        |
| <b>MMRd /MSI high</b>          | Anomaly in the DNA* repair system named MMR deficiency (= Mismatch repair deficiency)                                                                                                                                                                                                                                                                           |
| <b>Phytotherapy</b>            | Decrease in the number of neutrophils, belonging to the family of white blood cells (defense cells of the body), which can decrease the body's ability to fight infections.                                                                                                                                                                                     |

***\*Definition of words marked with an asterisk in the glossary***

|                               |                                                                                                                                                                                                                                                                                                                  |
|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>contrast agent</b>         | A substance used in medical imaging, which artificially increases the contrast to visualize an anatomical structure (for example, an organ) or pathological structure (for example, a tumor) naturally little or not contrasted, and which would therefore be difficult to distinguish from neighboring tissues. |
| <b>Study treatment</b>        | Investigational drug under evaluation                                                                                                                                                                                                                                                                            |
| <b>Sponsor</b>                | Legal person or institution, who is at the initiative of the research and ensures its support.                                                                                                                                                                                                                   |
| <b>Proteins</b>               | Biological large molecules present in all living cells that perform a multitude of functions within tissue cells.                                                                                                                                                                                                |
| <b>Randomization</b>          | Random allocation of one of the study treatments by drawing lots.                                                                                                                                                                                                                                                |
| <b>Tolerance</b>              | Ability of the body to withstand without an inconvenient effect the administration of a treatment.                                                                                                                                                                                                               |
| <b>Toxicity</b>               | All the adverse/side effects of a substance (e.g. a medicinal product) on an organism.                                                                                                                                                                                                                           |
| <b>Treatment</b>              | All medical cares which aim is to fight the disease, to limit its consequences, maintain or restore health and potentially lead to recovery.                                                                                                                                                                     |
| <b>Translational research</b> | Additional research-related analysis of e.g. blood, tumor or fecal samples which allow the scientist to obtain more information about cancer disease and the interaction of medications on e.g. tumor cells.                                                                                                     |
| <b>Immune system</b>          | A complex network of cells, tissues, organs, and the substances they make that helps the body fight infections and other diseases.<br>The immune system includes white blood cells and organs and tissues of the lymph system, such as the thymus, spleen, tonsils, lymph nodes, lymph vessels, and bone marrow. |
| <b>Versus</b>                 | Compared to                                                                                                                                                                                                                                                                                                      |
| <b>Cross-over</b>             | Change of treatment group you were randomised in when your study progresses and approval is granted (eg : from Group 1 treated by dostarlimab switching to chemotherapy treatment; or from Group 2 treated by chemotherapy switching to dostarlimab treatment.                                                   |
| <b>PK</b>                     | Pharmacokinetics : to measure dostarlimab rate in your blood                                                                                                                                                                                                                                                     |
| <b>IG</b>                     | Immunogenicity : to define the specific antibodies that can bind to dostarlimab during treatment                                                                                                                                                                                                                 |

**DOMENICA study**

**Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting**

**N° EudraCT: 2021-002124-21 / EU-CT: 2023-510097-14-00**

I, the undersigned (name, surname)..... been born on  
..... / ..... / .....

**Certify that I have read the information contained in the Patient Information Form (pages 1 to 20) of this document.**

Doctor..... provided me with all the information I wanted about the study objectives, treatment conditions and medical monitoring, its duration, its efficacy and side effects. I had the opportunity to ask all necessary questions to my understanding of the study.

I understood well how my personal data and my biological samples will be collected and analyzed.

At any time, I could ask additional information to my physician, Doctor.....  
at the following phone number: .....

I certify that I am affiliated with or benefit from a social security scheme.

I have the right to refuse to participate in the research. I also have the right to interrupt my participation or to withdraw my consent at any time without having to justify my decision. This will not affect the future course or quality of my care by the medical team.

I understand that the investigator (doctor) may interrupt my participation in the research at any time if he/she deems it necessary.

I have noted that I have the right to access, rectify, limit and oppose the treatment of my personal data. These rights can be exercised in the first place with the investigator (doctor) who is following me in this research and who knows my identity

I am aware that this study has been approved by local CA on the xx/ xx /xxxx and got the favorable opinion of the Ethic Committee YYYY on the xx/ xx /xxxx. The sponsor has taken out an insurance with the company (local company) to cover risks.

My consent does not relieve my investigator doctor and the sponsor of their responsibilities to me. I retain all my rights under the law.

The overall results of the research will be provided to me at the end of the research, if I request it from the investigator (doctor).

Two original copies of this consent form have been prepared: one has been given to me, the second has been kept by the investigator (doctor). It will be kept in the study file for at least 25 years after the end of the research.

**Under the conditions specified in the Patient Information Form (pages 1 to 21) of this document, a negative answer to one of the below questions implies my non-participation in this research:**

|                                                                                                                                                                                                                                |                                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| I freely agree to take part in the DOMENICA study                                                                                                                                                                              | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |
| I freely accept that blood samples should be collected and used for biological research purposes (including constitutional DNA* analysis). <i>If I answer « No », I will not be able to participate in the DOMENICA study.</i> | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |

**Under the conditions specified in the Patient Information Form (pages 1 to 17) of this document, a negative answer to any of the below questions will have no impact on my participation this research:**

|                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| I freely accept that 2 tumor samples collected before I enter in the study be used for biological research purposes.                                                                                                                                                                                                                                                                      | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |
| In case of progression, I freely accept that blood and tumor samples should be collected and used for Translational Research                                                                                                                                                                                                                                                              | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |
| I freely agree that my coded personal data and unused biological samples may be used for further research exclusively for scientific purposes in the field of cancer, including genetic research, and I understand that I can withdraw my consent at any time. The research projects will be available on the sponsor's website <a href="http://www.arcagy.org">http://www.arcagy.org</a> | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |
| I freely accept that blood samples should be collected and used for the secondary optional biological study detailed in section 2.5                                                                                                                                                                                                                                                       | <input type="checkbox"/> YES<br><input type="checkbox"/> NO |

|                                                                             |                                                                                  |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| <b><u>PATIENT</u></b><br><br>Name:<br><br><br>Date :<br><br><br>Signature : | <b><u>INVESTIGATOR</u></b><br><br>Name:<br><br><br>Date :<br><br><br>Signature : |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------|